Residual Plasma Concentration of Sorafenib and Adverse Events in CHC
NCT03340636
·
clinicaltrials.gov ↗
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Advanced or Metastatic Hepatocellular Carcinoma
Sponsor
University Hospital, Caen